Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers
NCT ID: NCT06171971
Last Updated: 2023-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
230 participants
OBSERVATIONAL
2022-06-20
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histological carcinological diagnosis performed at HUS
* Carcinological follow-up performed at HUS
* Patients with a solid tumor of unfavorable prognosis, refractory or in relapse
* Molecular analysis performed on tumor or blood samples
* Adult patients who do not object to the re-use of their personal data for medical research purposes
* Minor patients and their parents who do not object to the re-use of their personal data for scientific research purposes.
Criteria for non-inclusion
* Molecular biology results not usable due to poor sample quality or insufficient genetic material
* Patients who have expressed their opposition to participate in the study
* Parental authority holders who have expressed their opposition to participate in the study
1 Year
22 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Strasbourg, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service d'onco-hématologie pédiatrique - CHU de Strasbourg - France
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Natacha ENTZ-WERLE, MD, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
8661
Identifier Type: -
Identifier Source: org_study_id